EUCTR2018-002108-15-BE进行中（未招募）1 期
Phase 1/2 Study of BMS-986310 Administered Alone and in Combination with Nivolumab in Participants with Advanced Solid Tumors
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 280
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Patients with measurable disease per RECIST v1.1 and have at least one lesion accessible for biopsy.
- •- ECOG performance status less than or equal to 1
- •Part 1 and Sub-study B:
- •i) Part 1 participants must have advanced or metastatic disease where no other standard of care treatment option is possible.
- •ii) Sub-study B participants must have advanced or metastatic disease where no other standard of care treatment is possible, and they must have had disease progression on an anti-PD-(L)1 based regimen as their most recent prior therapy;
- •Tumor size equal to or greater than 1 cm
- •Sub-study A:
- •i) Males and females with histologically confirmed TNBC with no prior treatment for TNBC
- •i) Patients with NSCLC
- •ii) Patients with Pancreatic Cancer
- •iii) Patients with TNBC
- •iiii) Patients with CRC
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 168
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 112
排除标准
- •- History of severe adverse drug reactions to nonsteroidal anti-inflammatory drugs (NSAIDs), or those with adverse reactions to an NSAID that is currently prescribed
- •- Participants with an active, known or suspected autoimmune disease.
研究者
相似试验
进行中（未招募）
1 期
An investigational immunotherapy study of BMS-986310 administered alone and in combination with Nivolumab in patients with advanced solid tumorsAdvanced Solid TumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2018-002108-15-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO280
进行中（未招募）
1 期
Study of BMS-986179 Administered alone and in Combination with Nivolumab (BMS- 936558) in Subjects with Advanced Solid TumorsSolid tumorsMedDRA version: 20.0 Level: LLT Classification code 10065252 Term: Solid tumor System Organ Class: 100000004864EUCTR2016-000603-91-DEBristol-Myers Squibb International Corporation246
进行中（未招募）
1 期
A Phase 1/2 Study of BMS-986408 with and without Nivolumab or Nivolumab and Ipilimumab in Participants with Solid TumorsAdvanced Solid TumoursMedDRA version: 21.0Level: LLTClassification code: 10049280Term: Solid tumour Class: 10029104CTIS2022-500823-61-00Bristol-Myers Squibb International Corporation136
招募中
1 期
A Phase 1/2 Study of BMS-986449 with and without Nivolumab in Participants with Solid TumorsAdvanced, metastatic, solid malignancyMedDRA version: 20.0Level: LLTClassification code: 10025648Term: Malignant mast cell tumors unspecified site extranodal and solid organ sites Class: 10029104CTIS2023-503484-42-00Bristol-Myers Squibb Services Unlimited Company98
进行中（未招募）
1 期
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced CancersAdvanced Malignant TumorsMedDRA version: 20.0Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 100000004864EUCTR2015-004914-79-PLBristol-Myers Squibb International Corporation907